Evidence map›Paper›PMID 42145773›Full record

ArticleFrontiers in medicine2026

Association of vitreous CREG1 with diabetic macular edema response and edema resolution following ranibizumab therapy.

Linling Zhu, Dongmei Ding, Haixiang Xiao, Ying Cao, Danni Li, Gang Cao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Linling Zhu *Lixiang Eye Hospital of Soochow University, Suzhou, Jiangsu, China.
Dongmei Ding *Department of Ophthalmology, Huizhou Hospital of Traditional Chinese Medicine, Huizhou, Guangzhou, China.
Haixiang XiaoLixiang Eye Hospital of Soochow University, Suzhou, Jiangsu, China.
Ying CaoLixiang Eye Hospital of Soochow University, Suzhou, Jiangsu, China.
Danni LiLixiang Eye Hospital of Soochow University, Suzhou, Jiangsu, China.
Gang CaoLixiang Eye Hospital of Soochow University, Suzhou, Jiangsu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: This study examined the association between vitreous cellular repressor of E1A-stimulated genes 1 (CREG1) levels and the therapeutic response to ranibizumab in patients with diabetic macular edema (DME). Methods: In this retrospective study, 189 DME patients receiving ranibizumab were categorized into responders ( Results: Non-responders had a higher prevalence of serous retinal detachment and elevated HbA1c, neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR), but lower CREG1 and estimated glomerular filtration rate (eGFR) (all Conclusion: Lower vitreous CREG1 is associated with poor response to ranibizumab in DME. CREG1, along with OCT features, HbA1c, NLR, PLR, and eGFR, significantly influences treatment outcomes and correlates with long-term anatomical and visual prognosis.

Indexed as

anti-VEGF therapycellular repressor of E1A-stimulated genes 1diabetic macular edemadiabetic retinopathyranibizumab

Identifiers

PMID42145773
PMCPMC13171364

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.